THE USA, REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES;CODAGENIX, INC.
发明人:
Cyril LENOUEN,Ursula J. BUCHHOLZ,Peter L. COLLINS,Steffen MUELLER
申请号：
US16335099
公开号：
US20190233476A1
申请日:
2017.09.22
申请国别(地区):
US
年份:
2019
代理人:
摘要：
Reported herein are presumptively de-attenuating mutations that are useful, either individually or in combinations that may include other known mutations, in producing recombinant strains of human respiratory syncytial virus (RSV) exhibiting attenuation phenotypes. Also described herein is a novel RSV construct, Min_L-NPM2-1(N88K)L, which exhibits an attenuated phenotype, is stable and is as immunogenic as wild type RSV. The recombinant RSV strains described here are suitable for use as live-attenuated RSV vaccines. Exemplary vaccine candidates are described. Also provided are polynucleotide sequences capable of encoding the described viruses, as well as methods for producing and using the viruses.
